GlassScriptPhysician profile
Roger W Coomer
NPI 1720050990
$5,556.57
in general payments reported to CMS, 2019-2025
34 companies · $2,780 in 2025
The $2,780 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $372 · 2021: $293 · 2022: $515 · 2023: $532 · 2024: $742 · 2025: $2,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,372 · Consulting Fee: $1,650 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.67 |
| Consulting Fee | $1,650.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,650.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $466.18 | 2024-2025 | |
| Vifor Pharma, INC. | $459.72 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $349.65 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $323.33 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $271.65 | 2020-2025 | Farxiga, Lokelma |
| Amgen INC. | $256.68 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Novo Nordisk INC | $173.00 | 2022-2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $167.78 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $151.77 | 2021-2023 | Lupkynis |
| Travere Therapeutics, INC. | $138.59 | 2021-2025 | |
| Bard Peripheral Vascular, INC. | $136.04 | 2020 | |
| Lilly USA, LLC | $121.19 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $106.72 | 2022-2024 | |
| Akebia Therapeutics INC | $95.95 | 2020-2024 | Auryxia, Vafseo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.40 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $85.00 | 2022-2024 | Terlivaz |
| Glaxosmithkline, LLC. | $76.18 | 2020-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $53.95 | 2020-2022 | |
| Nxstage Medical, INC. | $51.96 | 2024 | |
| Fresenius USA Marketing, INC. | $50.28 | 2019-2023 | Velphoro |
| Ultragenyx Pharmaceutical INC. | $40.51 | 2021-2023 | |
| Daiichi Sankyo INC. | $33.04 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $31.53 | 2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $28.20 | 2019-2020 | |
| Cycle Pharmaceuticals INC | $25.85 | 2025 | Venxxiva |
| Takeda Pharmaceuticals U.S.A., INC. | $25.46 | 2020 | |
| Mallinckrodt Enterprises LLC | $17.12 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.75 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Genentech USA, INC. | $15.73 | 2019 | |
| Lemaitre Vascular, INC. | $13.52 | 2025 | Artegraft Vascular Graft |
| Medtronic, INC. | $11.28 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Coomer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.